Page 1

Exhibit 99.1 STRYKER REPORTS FIRST QUARTER 2021 OPERATING RESULTS Kalamazoo , Michigan - April 27 , 2021 - Stryker ( NYSE : SYK ) reported operating results for the first quarter of 2021 : The response to the COVID - 19 pandemic has included measures to slow the spread of the virus taken by governments and health care authorities globally , including the postponement of elective medical procedures and social contact restrictions . While there is starting to be some recovery in certain geographies , there continues to be a negative impact on our operations and financial results . First Quarter Results Reported net sales increased 10.2 % from 2020 and 12.4 % from 2019 to $ 4.0 billion • Organic net sales increased 1.8 % from 2020 and 4.7 % from 2019 • Reported operating income margin of 11.6 % • Adjusted operating income margin ( 1 ) contracted 50 bps to 23.5 % Reported EPS decreased 39.2 % to $ 0.79 Adjusted EPS ( ¹ ) increased 4.9 % to $ 1.93 In addition to sales growth analysis versus 2020 , we are including sales growth versus 2019 as 2019 provides a more normal baseline for comparison given the variability caused by the COVID - 19 pandemic throughout 2020 . First Quarter Net Sales Growth Overview From 2020 From 2019 Foreign Currency Reported Exchange Constant Currency Foreign Currency Acquisitions Orthopaedics MedSurg 21.4 % 2.7 % 1.6 18.7 % ( 1.6 ) 18.2 % Neurotechnology and Spine 14.0 2.7 11.3 Organic 0.5 % ( 1.6 ) 11.3 Reported Exchange Constant Currency Acquisitions Organic 18.7 % 6.2 1.5 % 17.2 % 17.9 % ( 0.7 ) % 0.9 5.3 5.3 14.6 1.8 12.8 12.8 Total 10.2 % 2.2 % 8.0 % 6.2 % 1.8 % 12.4 % 1.3 % 11.1 % 6.4 % 4.7 % " We are pleased with our results , as business picked up meaningfully in the latter part of the first quarter , " said Kevin Lobo , Chairman and Chief Executive Officer . " We expect this momentum to continue and are encouraged by the Wright Medical integration , which is pacing ahead of our expectations . " Sales Analysis Compared to 2020 and 2019 Consolidated net sales of $ 4.0 billion increased 10.2 % in the quarter and 8.0 % in constant currency from 2020. Organic net sales increased 1.8 % in the quarter including 2.7 % from increased unit volume partially offset by 0.9 % from lower prices . From 2019 consolidated net sales increased 12.4 % in the quarter and 11.1 % in constant currency . Organic net sales increased 4.7 % in the quarter including 6.1 % from increased unit volume partially offset by 1.4 % from lower prices . Orthopaedics net sales of $ 1.5 billion increased 21.4 % in the quarter and 18.7 % in constant currency from 2020. Organic net sales increased 0.5 % in the quarter including 2.6 % from increased unit volume partially offset by 2.1 % from lower prices . From 2019 Orthopaedics net sales increased 18.7 % in the quarter and 17.2 % in constant currency . Organic net sales decreased 0.7 % in the quarter including 2.7 % from increased unit volume offset by 3.4 % from lower prices . MedSurg net sales of $ 1.6 billion remained flat in the quarter and decreased 1.6 % in constant currency from 2020. Organic net sales decreased 1.6 % in the quarter including 1.4 % from decreased unit volume and 0.2 % from lower prices . From 2019 MedSurg net sales increased 6.2 % in the quarter and 5.3 % in constant currency . Organic net sales increased 5.3 % in the quarter from increased unit volume . Neurotechnology and Spine net sales of $ 0.8 billion increased 14.0 % in the quarter and 11.3 % in constant currency from 2020. Organic net sales increased 11.3 % in the quarter including 11.9 % from increased unit volume partially offset by 0.6 % from lower prices . From 2019 Neurotechnology and Spine net sales increased 14.6 % in the quarter and 12.8 % in constant currency . Organic net sales increased 12.8 % in the quarter including 13.4 % from increased unit volume partially offset by 0.6 % from lower prices . Earnings Analysis Compared to 2020 Reported net earnings of $ 302 million decreased 38.7 % in the quarter . Reported net earnings per diluted share of $ 0.79 decreased 39.2 % in the quarter . Reported gross profit margin and reported operating income margin were 63.5 % and 11.6 % in the quarter . Reported net earnings include certain items , such as charges for acquisition and integration - related activities , the amortization of purchased intangible assets , restructuring - related and other charges , costs to comply with certain medical device regulations , recall - related matters , regulatory and legal matters and tax matters . Excluding the aforementioned items , adjusted gross profit margin ( ¹ ) was 65.4 % in the quarter , and adjusted operating income margin ( 1 ) was 23.5 % in the quarter , a decline of 50 basis points . Adjusted net earnings ( 1 ) of $ 737 million increased 5.4 % in the quarter . Adjusted net earnings per diluted share ( ¹ ) of $ 1.93 increased 4.9 % in the quarter . 1